The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis

Sheena L Dupuy; Fariha Khalid; Brian C Healy; Sonya Bakshi; Mohit Neema; Shahamat Tauhid; Rohit Bakshi

doi:10.1186/s12880-016-0158-4

Back

The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis

Journal article

Open access

Peer reviewed

The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis

Sheena L Dupuy, Fariha Khalid, Brian C Healy, Sonya Bakshi, Mohit Neema, Shahamat Tauhid and Rohit Bakshi

BMC medical imaging, Vol.16(1), pp.56-56

10/05/2016

DOI: 10.1186/s12880-016-0158-4

PMCID: PMC5053209

PMID: 27716096

Files and links (1)

url

https://doi.org/10.1186/s12880-016-0158-4View

Published (Version of record) Open Access

Abstract

Spinal cord atrophy occurs early in multiple sclerosis (MS) and impacts disability. The therapeutic effect of interferon beta-1a (IFNβ-1a) on spinal cord atrophy in patients with relapsing-remitting (RR) MS has not been explored. We retrospectively identified 16 consecutive patients receiving weekly intramuscular IFNβ-1a for 2 years [baseline age (mean ± SD) 47.7 ± 7.5 years, Expanded Disability Status Scale score median (range) 1.5 (0-2.5), timed 25-foot walk 4.6 ± 0.7 seconds; time on treatment 68.3 ± 59.9 months] and 11 sex- and age-matched normal controls (NC). The spinal cord was imaged at baseline, 1 and 2 years later with 3T MRI. C1-C5 spinal cord volume was measured by an active surface method, from which normalized spinal cord area (SCA) was calculated. SCA showed no change in the MS or NC group over 2 years [mean annualized difference (95 % CI) MS: -0.604 mm (-1.352, 0.144), p = 0.106; NC: -0.360 mm (-1.576, 0.855), p = 0.524]. Between group analysis indicated no differences in on-study SCA change [MS vs. NC; year 1 vs. baseline, mean annualized difference (95 % CI) 0.400 mm (-3.350, 2.549), p = 0.780; year 2 vs. year 1: -1.196 mm (-0.875, 3.266), p = 0.245; year 2 vs. baseline -0.243 mm (-1.120, 1.607), p = 0.712]. Established IFNβ-1a therapy was not associated with ongoing spinal cord atrophy or any difference in the rate of spinal cord volume change in RRMS compared to NC over 2 years. These results may reflect a treatment effect. However, due to sample size and study design, these results should be considered preliminary and await confirmation.

Adjuvants, Immunologic - administration & dosage

Adjuvants, Immunologic - pharmacology

Adult

Drug Administration Schedule

Female

Humans

Injections, Intramuscular

Interferon beta-1a - administration & dosage

Interferon beta-1a - pharmacology

Magnetic Resonance Imaging - methods

Male

Middle Aged

Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging

Multiple Sclerosis, Relapsing-Remitting - drug therapy

Pilot Projects

Retrospective Studies

Spinal Cord - diagnostic imaging

Spinal Cord - drug effects

Treatment Outcome

Details

Title: Subtitle: The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis
Creators: Sheena L Dupuy - Brigham and Women's Hospital
Fariha Khalid - Brigham and Women's Hospital
Brian C Healy - Brigham and Women's Hospital
Sonya Bakshi - Brigham and Women's Hospital
Mohit Neema - Brigham and Women's Hospital
Shahamat Tauhid - Brigham and Women's Hospital
Rohit Bakshi - Brigham and Women's Hospital
Resource Type: Journal article
Publication Details: BMC medical imaging, Vol.16(1), pp.56-56
DOI: 10.1186/s12880-016-0158-4
PMID: 27716096
PMCID: PMC5053209
ISSN: 1471-2342
eISSN: 1471-2342
Language: English
Date published: 10/05/2016
Academic Unit: Psychiatry
Record Identifier: 9984627318202771

Metrics

5 Record Views

16 Times Cited - Web of Science

See more details